Skip to Content


Leukemia Insights Masthead

Leukemia Insights is a quarterly newsletter for physicians and other health professionals. Insights has the latest leukemia news, research and results from ongoing clinical trials, as well as available leukemia programs at MD Anderson.

Spring 2015: Vol. 20, No. 1

Immune Checkpoint Inhibitor Therapies in Hematologic Malignancies

Advances in immunotherapy research are providing new targets for drugs to treat acute myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative disorders and myelodysplastic syndromes. 

  • Introduction
  • Emergence of Checkpoint Inhibitors
  • Checkpoint Inhibitors in Hematologic Malignancies
  • Role of PD-1/PD-L1 Interactions in AML/MDS/CLL
  • Role of NK Cells and KIR Receptors in AML/MDS
  • Leukemia Priorities
  • Checkpoint Inhibitor Studies in AML
  • Checkpoint Inhibitor Studies in MDS
  • Checkpoint Inhibitor Study in MPN
  • Checkpoint and Other Immune-regulating Antibodies in CLL
  • Conclusion

Insights Staff

Editor: Hagop Kantarjian, M.D.
Associate Editor: Sherry Pierce, R.N.
Administrator: Vicky Zoeller